A Practical Approach to Echocardiographic Imaging

in Patients with Hypertrophic Cardiomyopathy

Resting and stress echocardiographic assessment of patients with hypertrophic cardiomyopathy (HCM), or concern for HCM, should follow HCM specific imaging protocol. The following is a practical
resource to help develop HCM imaging protocols and provides technical guidance for image and measurement acquisition in this cohort.
TECHNICAL CONSIDERATIONS FOR PERFORMING A RESTING ECHOCARDIOGRAM ON PATIENTS WITH HCM

Parasternal Strain
B-Mode 2D measurements end diastole. Strain Measure global longitudinal strain.
long axis LV IVS–end diastole. Record parametric ‘‘bull’s-eye’’ segmental strain
LV diameter–end diastole. map to assess for regional patterns in strain.
PW–end diastole. Regional longitudinal strain is reduced at sites of
hypertrophy and fibrosis.
Tips:
Measure only compacted myocardium (exclude RV structures). Tips:
Ensure apical views are not foreshortened.
Cross-reference with PSAX views.
Confirm that tracking is moving with the walls to
show areas of decreased strain.

B-Mode Evaluate for SAM of the MV leaflets.

Ultrasound Enhancing Agents(UEA)

M-Mode Evaluate leaflet tips throughout the cardiac cycle.
Long axis LV
M-mode may assist with evaluating timing of SAM (blue arrow).
Tips:
Scroll slowly through the image to define degree of SAM. UEA Tips:
4C, 2C, 3C Use to evaluate apical hypertrophy or those with
mid/distal cavity obstruction to evaluate for apical
aneurysm.
Color Doppler Evaluate for MR. Can improve accuracy of measured wall thickness
Long-axis LV in some cases.
Tips:
focus on MV
MR is typically posteriorly directed when related to SAM.
If MR is anteriorly directed, evaluate closely for intrinsic valve
disease. TECHNICAL CONSIDERATIONS FOR PERFORMING A STRESS ECHOCARDIOGRAM ON PATIENTS WITH HCM
The primary clinical utility of stress echocardiography in HCM is to identify occult LVOTO and dynamic MR.
UEA should not be utilized in the HCM stress echocardiography protocol as MV imaging is compromised
Medical therapies (such as Beta-blockers) should not be withheld prior to testing at the physiological response

Apical to exercise while taking medical therapy is clinically important.

B-Mode Focus on MV to evaluate for SAM.

Pre-exercise
5C and 3C Tips:
Note length of the MV leaflets in diastole if LVOTO. B-Mode Evaluate for level of obstruction (SAM with LVOTO vs
Note severity of SAM. 5C, 3C midcavity vs none).
Determine which view (5C or 3C) optimally evaluates
the MV and LVOT gradient and record cine clip.

Color Set color Doppler ROI over the LV and LA to assess

B-Mode Diastole Systole Measurement of MV leaflets 2D measurements. Doppler the level of obstruction and degree of MR.
Measurement Measure total length of the anterior and posterior leaflets of 5C and 3C This can be performed with B-mode imaging using
of MV leaflets the MV (gold lines) from annulus to leaflet tip in end diastole. Color Compare.
3C Measure the anterior and posterior residual leaflet
coaptation length (red lines) in the first frame of systole. Color Perform CW Doppler across the LVOT and measure
Tips: Doppler the peak gradient.
5C and 3C Document the heart rate.
A3C view is often the optimal view to measure MV leaflets.
PLAX view is an alternative option. If there is concern for contaminating MR, sweep the
Doppler beam from the LVOT into the MR and label.

Color Dopler Define level of obstruction with color Doppler. CW Doppler Evaluate and measure peak velocity across the
5C and 3C Tips: A4C tricuspid valve.
Set ROI to cover the entire LV from apex to the aortic
valve to define location of obstruction. B-Mode Perform routine LV exercise stress
Apical Views echocardiography views.
Compare the B-mode and color Doppler image
4C, 2C, 3C,
simultaneously to define the location of obstruction.
PLAX LV,
PSAC LV

Post-exercise
B-Mode Quickly evaluate for SAM.
5C, 3C UEA should not be used as the MV is the structure
of interest and it will not be seen with UEA.
*begin with the best view for evaluation of SAM
and LVOT gradient identified during rest imaging.
CW Doppler Quantify the severity of obstruction at rest.
5C and 3C CW Doppler measurement. Color Same as prior view.
Peak dynamic gradient. Doppler Set color Doppler ROI over the LV and LA to assess
Label, noting location of obstruction “e.g. resting LVOT gradient.” the level of obstruction and degree of MR.
Tips: This can be performed at the same time as the
B-mode imaging using Color Compare.
MR signal can contaminate the LVOT flow acceleration.
To evaluate for contamination, move the transducer more
CW Doppler Same as prior view.
laterally and angulate the probe to align the CW Doppler beam
post-exercise Place CW Doppler across the LVOT and measure
through the LVOT and aorta, avoiding the left atrium.
imaging the peak gradient.
Obtain and label LVOT jet then sweep the probe into the MR jet sequence
to highlight differences in velocities and Doppler profiles Perform as quickly as possible from the time
between the two jets. imaging begins using B-mode and color Doppler
data to align the Doppler beam.
If there is concern for contaminating MR, sweep the
Provocative Assess level of dynamic obstruction while patient performs a Doppler beam from the LVOT into the MR and label.
maneuvers provocative maneuver (Valsalva) in both the A5 and A3 chamber
B-mode and views
Color Doppler Tips:
5C and 3C
Practice the maneuver with the patient.
Define the best probe position to obtain optimal imaging during B-Mode (REPEAT using the second apical view)
provocation. 5C or 3C Quickly evaluate for SAM.
Record a cine clip while the maneuver is being performed with
B-mode and color Doppler to define whether SAM occurs/worsens Color (REPEAT using the second apical view)
or whether there is another location of worsening obstruction. Doppler Set color Doppler ROI over the LV and LA to assess
5C or 3C the imaging sequence level of obstruction and
Provocative degree of MR. This can be performed with B-mode
Quantify the severity of obstruction with provocation.
maneuvers imaging using Color Compare.
CW Doppler measurement:
CW Doppler
Peak dynamic gradient.
5C and 3C CW Doppler (REPEAT using the second apical view)
Label, noting location of obstruction and maneuver (e.g. LVOT 5C or 3C
gradient with Valsalva). Perform CW Doppler across the LVOT and
measure the peak gradient.

CW Doppler Evaluate and measure peak velocity

Color Doppler Evaluate change in MR. 4C tricuspid tricuspid valve.
3C, 4C, and 5C valve

B-Mode Perform routine LV exercise stress

Apical 4C, 2C, echocardiography views.
3C, PLAX LV,
PSAX LV

Evaluate for midcavity obstruction. Abbreviations:

Сolor Doppler reveals flow aliasing in the midventricle. 2C = Two-chamber GLS = Global longitudinal peak systolic strain PLAX = Parasternal long-axis
CW Doppler shows narrow flow acceleration in early systole 2D = Two-dimensional HCM = Hypertrophic cardiomyopathy PSAX = Parasternal shortaxis
3C = Three-chamber LA = Left atrial, atrium PW = Pulsed-wave
(yellow arrow) with a signal void in midsystole (blue arrow)
3D = Three-dimensional LV = Left ventricular, ventricle ROI = Region of interest
and an aortic closure click at end systole (red arrow), followed 4C = Four-chamber LVEF = Left ventricular ejection fraction RV = Right ventricular
by further flow in early diastole as blood is released from the 5C = Five-chamber LVOT = Left ventricular outflow tract SAM = Systolic anterior motion
high-pressure apical aneurysm into the LV chamber (white ASE = American Society LVOTO = Left ventricular outflow tract obstruction SRT = Septal reduction therapy
arrow). of Echocardiography MR = Mitral regurgitation TTE = Transthoracic echocardiography
CW = Continuous-wave MV = Mitral valve UEA = Ultrasound-enhancing agent

This piece was created from an article "A Practical Approach to Echocardiographic Imaging in Patients with Hypertrophic Cardiomyopathy" that was published in This product has been developed with support from Bristol Myers Squibb.
Access Additional
the Journal of the American Society of Echocardiography, September 2023 36(9) 913-932 © Соpyright 2024 The American Society of Echocardiography
Design by Ella Maru Studio ASE Hypertrophic
Authors of article: Carol C. Mitchell, PhD, ACS, RDMS, RDCS, RVT, RT(R); Cody Frye, BA, RDCS; Madeline Jankowski, BS, RDCS, ACS; John Symanski, MD; Steven J. Lester, M;,
Cardiomyopathy
Anna Woo, MD, SM; Yvonne Gilliland, MD; Andreea Dragulescu, MD; Theodore Abraham, MD; Milind Desai, MD; Matthew W. Martinez, MD; Sherif F. Nagueh, MD; and Dermot
Phelan, MD, PhD.
Resources